All Stories

  1. Zebrafish (Danio rerio) larvae as a predictive model to study gentamicin-induced structural alterations of the kidney
  2. Stability investigation of FCC-based tablets for oral suspension with caffeine and oxantel pamoate as model drugs
  3. Preclinical hazard evaluation strategy for nanomedicines
  4. Insights into possibilities for grouping and read-across for nanomaterials in EU chemicals legislation
  5. PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
  6. Characterization of new functionalized calcium carbonate-polycaprolactone composite material for application in geometry-constrained drug release formulation development
  7. Immobilization of Enzymes on PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer Deposition
  8. Current In Vitro Methods to Determine Hepatic Kp uu : A Comparison of Their Usefulness and Limitations
  9. Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial
  10. Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance
  11. Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations
  12. Pharmacokinetics of the antischistosomal lead OZ418 in uninfected mice determined by LC-MS/MS
  13. CombiCap: A novel drug formulation for the basel phenotyping cocktail
  14. Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial
  15. Interactions between silica nanoparticles and phospholipid membranes
  16. Mucoadhesive microparticles for local treatment of gastrointestinal diseases
  17. Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
  18. Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries
  19. Pediatric Dispersible Tablets: a Modular Approach for Rapid Prototyping
  20. Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients
  21. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data
  22. Isolation of multiantennary N-glycans from glycoproteins for hepatocyte specific targeting via the asialoglycoprotein receptor
  23. Functionalized Solid-Sphere PEG-b-PCL Nanoparticles to Target Brain Capillary Endothelial CellsIn Vitro
  24. Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: a parallel, randomised, controlled, dose-ranging study
  25. Development and validation of an enantioselective LC–MS/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots
  26. Technology, Applications, and Process Challenges of Dual Chamber Systems
  27. Nanomaterials: Therapeutic Applications
  28. Determination of the Density of Protein Particles Using a Suspended Microchannel Resonator
  29. Comparative safety evaluation of silica-based particles
  30. Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention
  31. Selective Oxidation of Methionine and Tryptophan Residues in a Therapeutic IgG1 Molecule
  32. An Impedance-Based Method to Determine Reconstitution Time for Freeze-Dried Pharmaceuticals
  33. In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets
  34. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles—Differential Centrifugation and FACS
  35. Marker-ion analysis for quantification of mucoadhesivity of microparticles in particle-retention assays
  36. Biocompatible Polymer–Peptide Hybrid-Based DNA Nanoparticles for Gene Delivery
  37. The extended clearance model and its use for the interpretation of hepatobiliary elimination data
  38. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor
  39. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlle...
  40. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
  41. LC–MS/MS method for the determination of two metabolites of tribendimidine, deacylated amidantel and its acetylated metabolite in plasma, blood and dried blood spots
  42. Translational Medicine: Nanoscience and Nanotechnology to Improve Patient Care
  43. Formation of lipid and polymer based gold nanohybrids using a nanoreactor approach
  44. Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins
  45. Polymersomes conjugated to 83-14 monoclonal antibodies: Invitro targeting of brain capillary endothelial cells
  46. High-throughput viscosity measurement using capillary electrophoresis instrumentation and its application to protein formulation
  47. Drug loading into porous calcium carbonate microparticles by solvent evaporation
  48. Floating gastroretentive drug delivery systems: Comparison of experimental and simulated dissolution profiles and floatation behavior
  49. Polymersomes containing quantum dots for cellular imaging
  50. Compaction of functionalized calcium carbonate, a porous and crystalline microparticulate material with a lamellar surface
  51. In Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs
  52. Oxantel Pamoate–Albendazole for Trichuris trichiura Infection
  53. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes
  54. Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue
  55. Efficacy and pharmacokinetics of OZ78 and MT04 against a natural infection with Fasciola hepatica in sheep
  56. Engineered nanomaterial uptake and tissue distribution: from cell to organism
  57. Indocyanine green loaded biocompatible nanoparticles: Stabilization of indocyanine green (ICG) using biocompatible silica-poly(ε-caprolactone) grafted nanocomposites
  58. Functionalized Calcium Carbonate as a Novel Pharmaceutical Excipient for the Preparation of Orally Dispersible Tablets
  59. A cell-based, multiparametric sensor approach characterises drug-induced cytotoxicity in human liver HepG2 cells
  60. Pharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies
  61. Stable human brain microvascular endothelial cell line retaining its barrier-specific nature independent of the passage number
  62. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters
  63. Computational Prediction of Blood-Brain Barrier Permeability Using Decision Tree Induction
  64. Drug interaction potential of resveratrol
  65. Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
  66. Evaluation of the pharmacokinetic profile of artesunate, artemether and their metabolites in sheep naturally infected with Fasciola hepatica
  67. A Binary Ant Colony Optimization Classifier for Molecular Activities
  68. P.1.c.017 Duloxetine prevents 3,4-methylenedioxymethamphetamine induced serotonin release in vitro and psychostimulant effects in humans
  69. On-line identification of P-glycoprotein substrates by monitoring of extracellular acidification and respiration rates in living cells
  70. In Vitro Assessment of the Formation of Ceftriaxone–Calcium Precipitates in Human Plasma
  71. Combinatorial QSAR Modeling of Human Intestinal Absorption
  72. Development and validation of a liquid chromatography and ion spray tandem mass spectrometry method for the quantification of artesunate, artemether and their major metabolites dihydroartemisinin and dihydroartemisinin-glucuronide in sheep plasma
  73. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists
  74. Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3
  75. Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep
  76. Development and validation of a liquid chromatography/mass spectrometry method for pharmacokinetic studies of OZ78, a fasciocidal drug candidate
  77. Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier
  78. Histamine-3 Receptor Inverse Agonists for the Treatment of Obesity: Validation of the Target and Identification of Novel Series
  79. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers
  80. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies
  81. In silico prediction of brain and CSF permeation of small molecules using PLS regression models
  82. Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2/3 antagonists
  83. Computational aqueous solubility prediction for drug-like compounds in congeneric series
  84. Tumor targeting using liposomal antineoplastic drugs
  85. Drug targeting using OX7-immunoliposomes: Correlation between Thy1.1 antigen expression and tissue distribution in the rat
  86. A potentiometric titration method for the crystallization of drug-like organic molecules
  87. Rational design, synthesis, and structure–activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure
  88. Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists
  89. Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists
  90. Induction of Cytochrome P450 3A4 and P-Glycoprotein by the Isoxazolyl- Penicillin Antibiotic Flucloxacillin
  91. 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers
  92. Drug transport to brain with targeted liposomes
  93. Drug transport to brain with targeted liposomes
  94. Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution andin vitropharmacological effects
  95. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes
  96. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam
  97. Impact of solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats
  98. Comparison of in Vitro P-Glycoprotein Screening Assays:  Recommendations for Their Use in Drug Discovery
  99. Examination of Blood-Brain Barrier Transferrin Receptor by Confocal Fluorescent Microscopy of Unfixed Isolated Rat Brain Capillaries
  100. Improved oral bioavailability of cyclosporin A in male Wistar rats
  101. By-passing of P-glycoprotein Using Immunoliposomes
  102. Endocytosis and Transcytosis of an Immunoliposome-Based Brain Drug Delivery System
  103. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
  104. Treatment of Large Solid Tumors in Mice with Daunomycin-Loaded Sterically Stabilized Liposomes
  105. High-performance liquid chromatographic method for an automated determination of local anaesthetics in human plasma
  106. Brain drug delivery of small molecules using immunoliposomes
  107. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium
  108. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation
  109. Are CCK-8 effects on food-intake mediated via direct access to the brain?
  110. Rapid and highly automated determination of morphine and morphine glucuronides in plasma by on-line solid-phase extraction and column liquid chromatography
  111. Leukotriene B4 formation upon halothane-induced lipid peroxidation in liver membrane fractions under low O2 concentrations in vitro
  112. Mechanisms of halothane toxicity: Novel insights
  113. Molecular mimicry of trifluoroacetylated human liver protein adducts by consitutive proteins and immunochemical evidence for its impairment in halothane hepatitis
  114. The kidney as a novel target tissue for protein adduct formation associated with metabolism of halothane and the candidate chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane
  115. Halothane metabolism. Impairment of hepatic omega-oxidation of leukotrienes in vivo and in vitro
  116. Exposure to the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane and the anesthetic agent halothane is associated with transient protein adduct formation in the heart
  117. Single-step organic extraction of leukotrienes and related compounds and their simultaneous analysis by high-performance liquid chromatography